Biovica International AB (publ) (STO:BIOVIC.B)
0.3600
+0.0180 (5.26%)
At close: Mar 27, 2026
Biovica International AB Revenue
Biovica International AB had revenue of 3.29M SEK in the quarter ending January 31, 2026, with 45.69% growth. This brings the company's revenue in the last twelve months to 10.93M, up 33.38% year-over-year. In the fiscal year ending April 30, 2025, Biovica International AB had annual revenue of 8.65M with 18.53% growth.
Revenue (ttm)
10.93M
Revenue Growth
+33.38%
P/S Ratio
9.62
Revenue / Employee
455.21K
Employees
24
Market Cap
105.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 8.65M | 1.35M | 18.53% |
| Apr 30, 2024 | 7.30M | 2.08M | 39.99% |
| Apr 30, 2023 | 5.21M | 113.00K | 2.22% |
| Apr 30, 2022 | 5.10M | -2.38M | -31.84% |
| Apr 30, 2021 | 7.48M | -2.20M | -22.71% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 296.57M |
| Xbrane Biopharma AB | 152.35M |
| IRLAB Therapeutics AB | 57.46M |
| Alzinova AB | 26.80M |
| Scandinavian ChemoTech AB | 12.29M |
| Alligator Bioscience AB | 4.42M |
| OncoZenge AB | 2.78M |
| Biosergen AB | 2.09M |